布鲁克 2024年度报告

2024 ANNUAL REPORT Shaping the Future Innovation with Integrity Dear Fellow Bruker Shareholders, 2024 was a transformational year forBruker. We completed several strategicacquisitions to access very largeaddressable markets with strong seculartailwinds. In the process, we added keyspatial biology, molecular diagnostics andlab automation platforms to our portfolio.With approximately 70% cumulativerevenue growth in the last four years,we have now achieved significant scale.In 2024, we delivered revenues over$3.3 billion, reflecting year-over-yeargrowth of 13.6%, including 4.0% organicgrowth, which was well above thebroader Life Science Tools & Diagnosticsmarket, which we estimate to havedeclined slightly in the year. To this, therecent strategic acquisitions added 10%inorganic revenue growth. We generatednon-GAAP earnings per share (EPS)of $2.41, as we work to overcome theinitial dilution from the aforementionedacquisitions. Expanding into New Markets through StrategicAcquisitions In 2024, we expanded into adjacent markets through strategicacquisitions, most notably ELITech, Chemspeed, andNanoString. ELITech, acquired in April 2024, greatly enhancesour molecular diagnostics capabilities by adding sample-to-answer PCR systems for mid-throughput testing & esotericparameters, including a broad infectious disease menu. Thiscomplements our established MALDI Biotyper® platform,and helps increase our aftermarket mix with significantconsumables revenue. This was also accretive to full companynon-GAAP operating margins and non-GAAP EPS on day one.Chemspeed expands our reach into laboratory automation anddigital solutions, positioning us well in an increasingly digitizedscientific environment. Finally, the acquisition of NanoStringprovides a strong foothold in spatial transcriptomics,complementing our existing Canopy Biosciences spatialproteomics offering. Though initially dilutive, we are workingdiligently to right-size this business and put it on the pathto profitability in the near future. The integration of thesebusinesses into Bruker is going well and position the companyfor strong growth and margin expansion in the years to come. Establishing the Bruker Spatial Biology Division The creation of the Bruker Spatial Biology Division marksa significant milestone in our go-to-market approach inspatial biology. Integrating NanoString, Canopy Biosciences,and Bruker Spatial Genomics (formerly Acuity SpatialGenomics) this division positions us at the forefront of spatialtranscriptomics and proteomics research, critical areas forbreakthrough discoveries in oncology, neuroscience, infectiousdisease, and developmental biology. Combining thesecomplementary businesses into one division allows us torealize meaningful synergies, both in the sales process as wellas in the operational cost structure. With our comprehensivespatial offering, we are uniquely equipped to supportresearchers as they address some of the most pressingbiological questions of our time. Innovation Leadership: New Product Launches Innovation remains the lifeblood of Bruker. Our product pipeline delivered meaningfuladvancements again in 2024, highlighted by the launch of our timsTOF Ultra 2 withunprecedented sensitivity, enabling significant further improvements in deep, high-fidelity 4D-Proteomics. Additionally, our new neofleX™ MALDI-TOF mass spectrometryimaging system sets new standards in spatial biology applications, while our enhancedNMR platforms provide unprecedented sensitivity and resolution for both life scienceand materials research. Bruker further advanced the CellScape chemistry with EpicIF(Enhanced photobleaching in cyclic immunofluorescence), which expands the range ofcompatible commercially available fluorophore conjugated antibodies nearly 10 times,simplifies assay development, and doubles throughput. These innovations are just someof the examples of our disciplined entrepreneurialism, and we continuously innovatewith many other novel, unique and high-value products and solutions. Comprehensive Battery Research In response to global demands for better, cleaner, forms of energy, we have significantlyexpanded our analytical tools across the battery value chain—from raw materialassessment to recycling processes and sustainability analytics. Bruker’s analyticalsolutions play an essential role in advancing safer, more efficient, sustainable energytechnologies, reinforcing our commitment to responsible innovation. Outlook: Navigating Challenges with Disciplined Entrepreneurialism As we look to 2025, we remain both ambitious and mindful of the complex challengeswe face. The current macroeconomic landscape, characterized by uncertaintyin academic research funding, geopolitical tensions, and ongoing global tariffconsiderations, necessitates continued prudence. Bruker will steadfastly apply ourprinciples of disciplined entrepreneurialism, proactively managing these headwindsto sustain our growth momentum and ensure long-term resilience. O